Literature DB >> 11238027

Alzheimer's disease in man and transgenic mice: females at higher risk.

R S Turner1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238027      PMCID: PMC1850377          DOI: 10.1016/S0002-9440(10)64026-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  66 in total

1.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Authors:  H L Weiner; C A Lemere; R Maron; E T Spooner; T J Grenfell; C Mori; S Issazadeh; W W Hancock; D J Selkoe
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

3.  Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.

Authors:  S J Haugabook; T Le; D Yager; B Zenk; B M Healy; E A Eckman; C Prada; L Younkin; P Murphy; I Pinnix; L Onstead; K Sambamurti; T E Golde; D Dickson; S G Younkin; C B Eckman
Journal:  FASEB J       Date:  2000-11-09       Impact factor: 5.191

4.  Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.

Authors:  K R Bales; T Verina; R C Dodel; Y Du; L Altstiel; M Bender; P Hyslop; E M Johnstone; S P Little; D J Cummins; P Piccardo; B Ghetti; S M Paul
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

5.  APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1.

Authors:  M C Irizarry; M McNamara; K Fedorchak; K Hsiao; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  1997-09       Impact factor: 3.685

6.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

7.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Authors:  C Janus; J Pearson; J McLaurin; P M Mathews; Y Jiang; S D Schmidt; M A Chishti; P Horne; D Heslin; J French; H T Mount; R A Nixon; M Mercken; C Bergeron; P E Fraser; P St George-Hyslop; D Westaway
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

8.  Neuroscience. An antibiotic to treat Alzheimer's?

Authors:  L Helmuth
Journal:  Science       Date:  2000-11-17       Impact factor: 47.728

9.  Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

Authors:  L M Refolo; B Malester; J LaFrancois; T Bryant-Thomas; R Wang; G S Tint; K Sambamurti; K Duff; M A Pappolla
Journal:  Neurobiol Dis       Date:  2000-08       Impact factor: 5.996

10.  Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease.

Authors:  T Wyss-Coray; E Masliah; M Mallory; L McConlogue; K Johnson-Wood; C Lin; L Mucke
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

View more
  11 in total

1.  CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Valerie Vingtdeux; Philippe Marambaud; Cristina d'Abramo; Heidy Jimenez; Mark Stauber; Rachel Friedman; Peter Davies
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

2.  Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice.

Authors:  Jen-Tzer Gau; Michelle L Steinhilb; Tzu-Cheg Kao; Constance J D'Amato; James R Gaut; Kirk A Frey; R Scott Turner
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

3.  Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain.

Authors:  Toshio Ariga; Makoto Yanagisawa; Chandramohan Wakade; Susumu Ando; Jerry J Buccafusco; Michael P McDonald; Robert K Yu
Journal:  ASN Neuro       Date:  2010-10-04       Impact factor: 4.146

4.  Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice.

Authors:  René Etcheberrigaray; Mathew Tan; Ilse Dewachter; Cuno Kuipéri; Ingrid Van der Auwera; Stefaan Wera; Lixin Qiao; Barry Bank; Thomas J Nelson; Alan P Kozikowski; Fred Van Leuven; Daniel L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

5.  Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease.

Authors:  Kevin A Corcoran; Ye Lu; R Scott Turner; Stephen Maren
Journal:  Learn Mem       Date:  2002 Sep-Oct       Impact factor: 2.460

6.  CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Valerie Vingtdeux; Philippe Marambaud; Cristina d'Abramo; Heidy Jimenez; Mark Stauber; Rachel Friedman; Peter Davies
Journal:  Mol Med       Date:  2014-03-14       Impact factor: 6.354

Review 7.  Uses for humanised mouse models in precision medicine for neurodegenerative disease.

Authors:  Remya R Nair; Silvia Corrochano; Samanta Gasco; Charlotte Tibbit; David Thompson; Cheryl Maduro; Zeinab Ali; Pietro Fratta; Abraham Acevedo Arozena; Thomas J Cunningham; Elizabeth M C Fisher
Journal:  Mamm Genome       Date:  2019-06-15       Impact factor: 2.957

8.  Caspase-6 Knockout in the 5xFAD Model of Alzheimer's Disease Reveals Favorable Outcome on Memory and Neurological Hallmarks.

Authors:  Ariel Angel; Rotem Volkman; Tabitha Grace Royal; Daniel Offen
Journal:  Int J Mol Sci       Date:  2020-02-09       Impact factor: 5.923

9.  Expression of Phenotypic Astrocyte Marker Is Increased in a Transgenic Mouse Model of Alzheimer's Disease versus Age-Matched Controls: A Presymptomatic Stage Study.

Authors:  Aurélie Doméné; Chelsea Cavanagh; Guylène Page; Sylvie Bodard; Christophe Klein; Cécile Delarasse; Sylvie Chalon; Slavica Krantic
Journal:  Int J Alzheimers Dis       Date:  2016-09-08

Review 10.  An Overview of Astrocyte Responses in Genetically Induced Alzheimer's Disease Mouse Models.

Authors:  Fokion Spanos; Shane A Liddelow
Journal:  Cells       Date:  2020-11-04       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.